A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Zhang, Xudong; Wang, Wenhua; Ma, Shanshan; Fan, Mengke; Zhu, Linan; Zhang, Lei; Li, Xin; Li, Ling; Sun, Zhenchang; Wang, Xinhua; Fu, Xiaorui; Li, Zhaoming; Yan, Jiaqin; Zhang, Mingzhi

doi:10.1182/blood-2022-159383

Blood

2022

DOI: 10.1182/blood-2022-159383

|View full text |Cite

A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Xudong Zhang

Wenhua Wang

Shanshan Ma

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Cited by 1 publication

References 0 publications

The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies

The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies

Contact Info

Product

Resources

About